# Concomitant Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Small Vessel Stroke

Study · id `cardio:ct-nct06358313` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06358313](<https://clinicaltrials.gov/study/NCT06358313>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06358313

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 600 participants.

## Technical summary

Registry record NCT06358313. Randomized; double masking; primary purpose treatment. Start 2024-04-10 (actual); primary completion 2026-05-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 600 participants (planned count; ClinicalTrials.gov record NCT06358313, source copy `cardio:ctgov-nct06358313-2026-04-23`, retrieved 2026-10-26)
- Started: 2024-04-10 (actual) (ClinicalTrials.gov record NCT06358313, source copy `cardio:ctgov-nct06358313-2026-04-23`, retrieved 2026-10-26)
- Primary completion: 2026-05-10 (anticipated) (ClinicalTrials.gov record NCT06358313, source copy `cardio:ctgov-nct06358313-2026-04-23`, retrieved 2026-10-26)
- Completion: 2026-05-30 (anticipated) (ClinicalTrials.gov record NCT06358313, source copy `cardio:ctgov-nct06358313-2026-04-23`, retrieved 2026-10-26)
- Countries: Egypt (ClinicalTrials.gov record NCT06358313, source copy `cardio:ctgov-nct06358313-2026-04-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06358313-2026-04-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Concomitant Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Small Vessel Stroke
- Condition: Ischemic Stroke
- Intervention (Drug): Atorvastatin 40mg
- Intervention (Drug): Rosuvastatin 20mg
- Lead sponsor: Kafrelsheikh University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention is a member of this class by a sourced record link: Statins (`cardio:statins`)
- Registry lists this organization as the lead sponsor: Kafrelsheikh University (`cardio:org-kafrelsheikh-university`)

## Provenance

Content hash: 2c70d39b1122bf7094d93708a71117d5f8401eea1c02c193ded8704f7178464b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
